Sildenafil

Generic Name: Sildenafil

Brand Names: Liqrev, Revatio, Viagra, Vizarsin, Sildenafil Actavis, Sildenafil ratiopharm, Granpidam, Sildenafil Teva, Mysildecard

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₀N_₆O_₄S

CAS Number: 139755-83-2

Unique Ingredient Identifier: 3M7OB98Y7H

Background: In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently faci...

Indication: Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:

(1) the treatment of erectile dysfunction ; and

(2) treatment of pulmonary hypertension, where:
...

Associated Conditions: Erectile Dysfunction, NYHA Functional Class II-III Pulmonary arterial hypertension, Premature Ejaculation, Pulmonary Arterial Hypertension (PAH)

Associated Therapies: -

Clinical Trials

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

Phase 4

Recruiting

Conditions: Peyronie Disease

Interventions: Drug: Collagenase Clostridium Histolyticum
Device: RestoreX
Drug: Sildenafil

First Posted Date: 2024-10-18

Last Posted Date: 2024-10-18

Lead Sponsor: Charitable Union for the Research and Education of Peyronie's Disease

Target Recruit Count: 40

Registration Number: NCT06649539

Locations: 🇺🇸
Male Fertility and Peyronie's Clinic, Orem, Utah, United States

Efficacy of Milrinone With Sildenafil in Persistent Pulmonary Hypertension in Children

Not Applicable

Completed

Conditions: Persistent Pulmonary Hypertension of the Newborn

Interventions: Drug: Sildenafil
Drug: Milrinone

First Posted Date: 2024-08-20

Last Posted Date: 2024-08-26

Lead Sponsor: Muhammad Aamir Latif

Target Recruit Count: 42

Registration Number: NCT06562036

Locations: 🇵🇰
Children's Hospital and institute of Child Health, Multan, Punjab, Pakistan

Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support

Early Phase 1

Not yet recruiting

Conditions: Vascular Diseases

Interventions: Other: Placebo
Drug: Sildenafil

First Posted Date: 2024-07-19

Last Posted Date: 2024-07-25

Lead Sponsor: Montefiore Medical Center

Target Recruit Count: 50

Registration Number: NCT06510322

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer

Phase 3

Not yet recruiting

Conditions: Rectal Cancer

Interventions: Drug: Sildenafil
Other: Placebo

First Posted Date: 2023-11-08

Last Posted Date: 2023-11-08

Lead Sponsor: University Hospital, Rouen

Target Recruit Count: 188

Registration Number: NCT06123156

Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia

Phase 2

Recruiting

Conditions: Neonatal Encephalopathy

Interventions: Drug: Ora-Blend
Drug: Sildenafil

First Posted Date: 2023-10-25

Last Posted Date: 2024-07-12

Lead Sponsor: Pia Wintermark

Target Recruit Count: 60

Registration Number: NCT06098833

Locations: 🇨🇦
Montreal Children's Hospital, Montréal, Quebec, Canada

Clinical Observation of Ningmitai Capsule in Treating Chronic Pelvic Pain Syndrome With Erectile Dysfunction

Phase 4

Completed

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Erectile Dysfunction

Interventions: Drug: Sildenafil
Drug: Ningmitai capsule
Drug: Ningbitai capsule + sildenafil

First Posted Date: 2023-10-03

Last Posted Date: 2023-10-12

Lead Sponsor: Xintian Pharmaceutical

Target Recruit Count: 254

Registration Number: NCT06064448

Locations: 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes

Phase 2

Not yet recruiting

Conditions: IVF

Interventions: Drug: pentoxifylline
Drug: tadalafil
Drug: Sildenafil

First Posted Date: 2023-08-02

Last Posted Date: 2023-08-03

Lead Sponsor: Beni-Suef University

Target Recruit Count: 200

Registration Number: NCT05971667

Locations: 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Beni Suef, Egypt

Effect of Sildenafil in Individuals With Migraine Pretreated With Erenumab

Not Applicable

Completed

Conditions: Migraine Without Aura

Interventions: Drug: Sildenafil
Other: Placebo

First Posted Date: 2023-06-05

Last Posted Date: 2023-10-24

Lead Sponsor: Danish Headache Center

Target Recruit Count: 16

Registration Number: NCT05889455

Locations: 🇩🇰
Danish Headache Center, Copenhagen, Denmark

Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%

Phase 1

Recruiting

Conditions: Sexual Arousal Disorder

Interventions: Drug: Placebo
Drug: Vehicle
Drug: Sildenafil

First Posted Date: 2023-03-13

Last Posted Date: 2024-01-11

Lead Sponsor: Daré Bioscience, Inc.

Target Recruit Count: 15

Registration Number: NCT05765487

Locations: 🇨🇦
Pharma Medica Research, Inc., Mississauga, Ontario, Canada

Effect of Sildenafil Citrate Compared to Estrogen as Adjuvant Therapy for Unexplained Infertility

Phase 4

Completed

Conditions: Subfertility, Female

Interventions: Drug: estrogen therapy
Drug: Sildenafil
Drug: Clomiphene Citrate 50mg

First Posted Date: 2023-03-03

Last Posted Date: 2023-04-28

Lead Sponsor: Beni-Suef University

Target Recruit Count: 148

Registration Number: NCT05753098

Locations: 🇪🇬
Beni-suef university, Banī Suwayf, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy